We read with great interest the recent paper by Donti et al. [1] on the diagnosis of adenylosuccinate lyase deficiency via plasma metabolomics. In their Supplementary Table S3, the authors provide the allele frequency for previously reported ADSL mutations. Based on this data, and adding the allele frequency of other pathogenic variants, one can estimate the minimal prevalence of the disease. The prevalence of adenylosuccinase deficiency remains unknown, with almost 80 patients reported to date [2].
Other than the previously reported mutations provided by the authors, one can mine ExAC for ADSL variants classified as pathogenic according to current ACMG variant interpretation guidelines, meaning variants with very strong evidence of pathogenicity (nonsense, frameshift or canonical splice site), extremely rare, with in silico algorithms predicting a deleterious effect on the gene product [3]. The allele frequencies of these variants are provided in Table 1. The total allele frequency is thus 109/121,412. By assuming Hardy-Weinberg equilibrium, where the allele frequency corresponds to q and the carrier frequency to 2pq, one can then estimate the disease frequency (q2). A similar approach has been recently used to calculate the frequency of other metabolic conditions, such as Smith-Lemli-Opitz syndrome [4], cerebrotendinous xanthomatosis [5], Niemann-Pick type C [6] and McArdle disease [7]. The prevalence of the adenylosuccinatase lyase deficiency is thus approximately 1 in 1,240,710, with a carrier frequency of 1 in 557. It should be noted that this carrier frequency is much higher than expected, as it was previously presumed to be around 1 in 10,000 [2].
Table 1.
ADSL truncating variants in ExAC with their respective allele frequencies.
| Chrom | Position | Ref | Alt | Transcript change | Protein change | Consequence | Allele count | Allele number | CADD Phred |
|---|---|---|---|---|---|---|---|---|---|
| 22 | 40749122 | G | T | c.402 + 1G > T | Splice donor | 1 | 121298 | 26.6 | |
| 22 | 40754866 | A | C | c.483 − 2A > C | Splice acceptor | 1 | 121410 | 25.4 | |
| 22 | 40755311 | G | A | c.701 + 1G > A | Splice donor | 1 | 121412 | 29.4 | |
| 22 | 40757347 | G | T | c.862 + 1G > T | Splice donor | 1 | 121402 | 27.8 | |
| 22 | 40758984 | G | A | c.1011 − 1G > A | Splice acceptor | 1 | 121408 | 26.6 | |
| 22 | 40757290 | T | TA | c.807dupA | p.Arg270Thrfs*14 | Frameshift | 1 | 121406 | 35 |
| 22 | 40760901 | CAG | C | c.1212_1213delAG | p.Arg404Serfs*11 | Frameshift | 1 | 121410 | 36 |
| 22 | 40760367 | C | T | c.1189C > T | p.Gln397* | Stop gained | 1 | 115304 | 43 |
| 22 | 40760914 | C | T | c.1222C > T | p.Gln408* | Stop gained | 1 | 121412 | 43 |
| 22 | 40742635 | G | T | c.73G > T | p.Glu25* | Stop gained | 1 | 92518 | 38 |
| 22 | 40760935 | AAG | A | c.1244_1245delAG | p.Lys415Thrfs*5 | Frameshift | 1 | 121410 | 35 |
| 22 | 40745835 | GA | G | c.154delA | p.Thr52Hisfs*14 | Frameshift | 1 | 119038 | 24.2 |
| 22 | 40742697 | G | A | c.135G > A | p.Trp45* | Stop gained | 1 | 95974 | 37 |
| 22 | 40761059 | AG | A | c.1368 + 1delG | Frameshift | 2 | 121402 | 35 |
This disease frequency of about 1 in 1.25 million corresponds in fact to a conservative estimate of its prevalence, as it is likely that other missense pathogenic mutations exist that have not yet been reported, and those were not taken into account for the calculation above.
Funding
Dr. Ferreira has no funding sources to declare related to the manuscript preparation.
References
- 1.Donti T.R., Cappuccio G., Hubert L., Neira J., Atwal P.S., Miller M.J., Cardon A.L., Sutton V.R., Porter B.E., Baumer F.M., Wangler M.F., Sun Q., Emrick L.T., Elsea S.H. Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrum. Mol. Genet. Metab. Rep. 2016;8:61–66. doi: 10.1016/j.ymgmr.2016.07.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Jurecka A., Zikanova M., Kmoch S., Tylki-Szymańska A. Adenylosuccinate lyase deficiency. J. Inherit. Metab. Dis. 2015;38:231–242. doi: 10.1007/s10545-014-9755-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., Voelkerding K., Rehm H.L. ACMG Laboratory Quality Assurance Committee, standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. Off. J. Am. Coll. Med. Genet. 2015;17:405–424. doi: 10.1038/gim.2015.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cross J.L., Iben J., Simpson C.L., Thurm A., Swedo S., Tierney E., Bailey-Wilson J.E., Biesecker L.G., Porter F.D., Wassif C.A. Determination of the allelic frequency in Smith-Lemli-Opitz syndrome by analysis of massively parallel sequencing data sets. Clin. Genet. 2015;87:570–575. doi: 10.1111/cge.12425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Appadurai V., DeBarber A., Chiang P.-W., Patel S.B., Steiner R.D., Tyler C., Bonnen P.E. Apparent underdiagnosis of cerebrotendinous xanthomatosis revealed by analysis of ~ 60,000 human exomes. Mol. Genet. Metab. 2015;116:298–304. doi: 10.1016/j.ymgme.2015.10.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Wassif C.A., Cross J.L., Iben J., Sanchez-Pulido L., Cougnoux A., Platt F.M., Ory D.S., Ponting C.P., Bailey-Wilson J.E., Biesecker L.G., Porter F.D. High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet. Med. Off. J. Am. Coll. Med. Genet. 2016;18:41–48. doi: 10.1038/gim.2015.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.De Castro M., Johnston J., Biesecker L. Determining the prevalence of McArdle disease from gene frequency by analysis of next-generation sequencing data. Genet. Med. Off. J. Am. Coll. Med. Genet. 2015;17:1002–1006. doi: 10.1038/gim.2015.9. [DOI] [PMC free article] [PubMed] [Google Scholar]